927525-03-9

Basic information

• Product Name: N,N-DiMethyl-3-azetidinecarboxaMide
• Synonyms: N,N-DiMethyl-3-azetidinecarboxaMide;N,N-DiMethyl-3-azetidinec...;N,N-dimethylazetidine-3-carboxamide
• CAS NO: 927525-03-9
• Molecular Formula: C₆H₁₂N₂O
• Molecular Weight: 128.17228
• Mol File: 927525-03-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N,N-DiMethyl-3-azetidinecarboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-DiMethyl-3-azetidinecarboxaMide(927525-03-9)
• EPA Substance Registry System: N,N-DiMethyl-3-azetidinecarboxaMide(927525-03-9)

Safety Data

• Hazardous Substances Data: 927525-03-9(Hazardous Substances Data)

Upstream product

• 1046469-16-2 tert-butyl 3-[(dimethylamino)carbonyl]azetidine-1-carboxylate 

Downstream Products

• 1046469-04-8 1-{[(8S)-2,3-dimethyl-8-(2-methylphenyl)-3,6,7,8-tetrahydrochromeno[7,8-d]imidazol-5-yl]carbonyl}-N,N-dimethylazetidine-3-carboxamide 

Relevant articles and documents

Tetrahydrochromenoimidazoles as potassium-competitive acid blockers (P-CABs): Structure-activity relationship of their antisecretory properties and their affinity toward the hERG channel

Potassium-competitive acid blockers (P-CABs) constitute a new therapeutic option for the treatment of acid-related diseases that are widespread and constitute a significant economical burden. Enantiomerically pure tetrahydrochromenoimidazoles were prepared using the readily available candidate 4 (BYK 405879) as starting material or the Noyori asymmetric reduction of ketones as key reaction. A comprehensive SAR regarding the influence of the 5-carboxamide and the 8-aryl residue on in vitro activity, acid-suppression in the Ghosh Schild rat, and affinity toward the hERG channel was established. In addition, efficacy and duration of the antisecretory action was examined for the most promising target compounds by 24 h pH-metry in the fistula dog and a significantly different SAR was observed as compared to the Ghosh Schild rat. Several tetrahydrochromenoimidazoles were identified that possessed a comparable profile as the candidate 4.

ENANTIOPURE PHARMACOLOGICALLY ACTIVE TRICYCLIC BENZIMIDAZOLES

The invention provides compounds of the formula (1) in which the substituents and symbols are as de fined in the description. The compounds inhibit the secretion of gastric acid.

Indolobenzazepine HCV NS5B inhibitors

The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.